The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
REGULATORY
Japan Panel OKs Basic Policy for Stockpiling Crisis-Response Medicines
A health ministry panel has approved a basic policy for stockpiling medical countermeasures (MCMs), setting out the objectives, selection criteria, and prioritization framework for medicines to be purchased and stored for use in public health emergencies. The policy was endorsed…
To read the full story
Related Article
- Japan Govt Council Discusses Draft Recommendations for National MCM Strategy
December 9, 2025
- Japan Govt Council Gathers Views to Shape National MCM Strategy
September 4, 2025
- Japan Panel Supports Plan to Prioritize MCM Development by Need and Feasibility
September 4, 2025
- Japan Moves to Bolster R&D and Stockpiling of Crisis-Response Medicines
August 20, 2025
- Health Ministry Presents Proposal to Revise Priority Infectious Diseases
March 12, 2025
- MHLW Issues Guidance on Early Approval Scheme for MCMs
November 8, 2024
- MHLW Council Endorses Early Approval Scheme for Medical Countermeasures
October 2, 2024
- Tentative List of Priority Infectious Diseases Expected by End of March
March 24, 2022
REGULATORY
- OTC-Like Drugs Left in Limbo as Panel Debates Cost-Sharing without Clear Policy Signal
December 19, 2025
- LDP, Ishin Fail to Seal Deal on OTC-Like Drugs as Talks Stall over Fiscal-Savings Figure
December 18, 2025
- Japan Moves LLP Payment Hike toward Political Call, Eyes 1/2 or Higher
December 18, 2025
- Panel to Weigh Orphan Designation for Tecartus on December 22
December 17, 2025
- LDP League Formally Urges Male HPV Shots Under NIP from FY2026
December 17, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…